Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer
Authors:
Open Access
- 8 June 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Abstract
Tumor cells have long been recognized as a relative contraindication to hyperbaric oxygen treatment (HBOT) since HBOT might enhance progressive cancer growth. However, in an oxygen deficit condition, tumor cells are more progressive and can be metastatic. HBOT increasing in oxygen partial pressure may benefit tumor suppression. In this study, we investigated the effects of HBOT on solid tumors, such as lung cancer. Non-small cell human lung carcinoma A549-cell-transferred severe combined immunodeficiency mice (SCID) mice were selected as an in vivo model to detect the potential mechanism of HBOT in lung tumors. HBOT not only improved tumor hypoxia but also suppressed tumor growth in murine xenograft tumor models. Platelet endothelial cell adhesion molecule (PECAM-1/CD31) was significantly increased after HBOT. Immunostaining of cleaved caspase-3 was demonstrated and apoptotic tumor cells with nuclear debris were aggregated starting on the 14th-day after HBOT. In vitro,HBOT suppressed the growth of A549 cells in a time-dependent manner and immediately downregulated the expression of p53 protein after HBOT in A549 cells. Furthermore, HBOT-reduced p53 protein could be rescued by a proteasome degradation inhibitor, but not an autophagy inhibitor in A549 cells. Our results demonstrated that HBOT improved tissue angiogenesis, tumor hypoxia and increased tumor apoptosis to lung cancer cells in murine xenograft tumor models, through modifying the tumor hypoxic microenvironment. HBOT will merit further cancer therapy as an adjuvant treatment for solid tumors, such as lung cancer.Keywords
All Related Versions
Funding Information
- National Science Council (NSC 93-2314-B-016-026)
- Tri-Service General Hospital (TSGH-C94-46)
- Cardinal Tien Hospital (CTH-106A-1-2A01, CTH-106A-2C02, CTH108A-2A03)
- Cheng Hsin General Hospital (CH-NDMC-108-02)
This publication has 43 references indexed in Scilit:
- Hyperbaric oxygen therapy and cancer—a reviewTargeted Oncology, 2012
- Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: Preliminary resultsInternational Journal of Hyperthermia, 2009
- PECAM-1: A Multi-Functional Molecule in Inflammation and Vascular BiologyArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Hyperbaric oxygen stimulates cell proliferation and normalizes multidrug resistance protein‐2 protein localization in primary rat hepatocytesWound Repair and Regeneration, 2005
- ‘Cross-talk’ between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesisCancer Letters, 2005
- Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumorsCancer Letters, 2004
- Tumor hypoxia: A target for selective cancer therapyCancer Science, 2003
- Early hyperbaric oxygen therapy attenuates disease severity in lupus-prone autoimmune (NZB × NZW) F1 miceClinical Immunology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Hyperbaric oxygen therapy for the treatment of radiation-induced sequelae in children: The University of Pennsylvania experienceCancer, 1996